Biopharma's China plan gets a boost from patent protections sealed in now official trade deal
As international relations experts continue to cast skepticism on the “phase one” US-China trade deal signed Wednesday, multinational drugmakers found much to be cheerful about.
Specifically, the document includes three provisions related to pharmaceutical patent dispute resolution, patent term extension and counterfeit medicines, promising to strengthen protection for drugs at a time China’s regulatory agency has sped up reviews and shortened the time gap between overseas and Chinese OKs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.